RHEINFELDEN, Switzerland, 17.05.2021 – Tillotts Pharma AG (“Tillotts”), part of the Japanese Zeria Group, is pleased to announce the launch of AsacolTM 1g (mesalazine), a high strength suppository indicated for treatment of adults with mild to moderate ulcerative proctitis symptoms.
AsacolTM 1g suppositories contain the active ingredient mesalazine (5-aminosalicylic acid) and are indicated for the treatment of mild to moderate Ulcerative Colitis limited to the rectum (ulcerative proctitis). The suppository is designed to promote soft, local relief for patients with an inflamed lining. With a single dose of AsacolTM 1g suppository per day, Tillotts offers a new patient-centric treatment. “Rectal formulations of mesalazine are an important component in the treatment scheme for ulcerative proctitis. They are under-utilised because of their embarrassing and inconvenient delivery route. We are pleased to add a high-strength suppository formulation to our mesalazine product range, allowing to reduce the number of daily applications. We are convinced that this will translate into better drug adherence and subsequently contribute to the well-being of our patients,” says Johannes Spleiss, Head of Scientific Affairs at Tillotts.
AsacolTM is available in 50 countries worldwide as AsacolTM and as Octasa®, Asacolon™ and Fivasa™ in the UK, Ireland and France, respectively. In the Netherlands, Austria and the Baltics it is marketed as Yaldigo®. Complementing the existing products including tablets in 400, 800 and 1600 mg strengths as well as enemas and suppositories, the new medication expands the Asacol range and further enhances the portfolio of Tillotts for the treatment of the digestive system.
With the marketing authorisation of AsacolTM respectively Octasa® 1g suppositories in February 2021, the United Kingdom is the first country to launch the new medication. “The launch of AsacolTM 1g suppositories is yet another milestone, broadening our strong mesalazine portfolio and providing healthcare professionals and ulcerative colitis patients with a high strength 1g suppository as a complement to our newly launched, highest strength mesalazine tablet, the AsacolTM 1600mg tablet. Both are registered for once daily use as a step towards improving patient convenience and adherence,” says Mattias Norrman, Chief Operations Officer at Tillotts.
Um die Pressemitteilung auf Deutsch zu lesen, klicken Sie hier
Pour lire le communiqué de presse en français cliquez ici
Asacol™ 1g suppositories
Asacol™ 1g suppositories (mesalazine) is a medicine for the treatment of the inflamed lining of the large bowel (colonic and rectal mucosa).
About Ulcerative Colitis
Ulcerative colitis (UC) is an inflammatory bowel disease that involves chronic inflammation of the lining of the large bowel. Unlike Crohn’s disease, which can occur anywhere along the digestive tract, UC only affects the colon and the rectum. UC causes swelling of the intestinal wall, in addition to inflammation of the large intestine. Symptoms vary, but often include diarrhoea and blood in the stools. UC is a chronic debilitating disease that may lead to potentially serious and life-threatening complications.
Reporting of Side Effects: At Tillotts Pharma, we continuously monitor the safety of our products by collecting information regarding side effects associated with their use. Any side effects or safety concerns may be reported by completing our online form in the section “Product Safety” on www.tillotts.com.
For further information, please contact:
Tillotts Pharma AG
Senior Manager Corporate Communications
Phone: +41 61 935 2759
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 300 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition and commercialisation of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own and in-licensed products for the treatment of IBD and C.Difficile infection in around 65 countries through its affiliates within Europe and a network of gastroenterology-focused partners throughout the world.
All trademarks used or mentioned here are protected by law. The rights to the trademark AsacolTM are owned by Tillotts in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg.
© Copyright by Tillotts Pharma AG 2021. All rights reserved.
For more information, please visit www.tillotts.com
Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries. For more information about Zeria, please visit www.zeria.co.jp
Download high-resolution photos here https://www.tillotts.com/about-us/visuals/.